SCHEMBL9582152

SCHEMBL9582152

ClCc1ncc(-c2ccccc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
NFKB1 P19838 2/20 0.54
NFKB2 Q00653 2/20 0.54
RELA Q04206 2/20 0.54
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
MAPT P10636 1/20 0.43
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
ACHE P22303 1/20 0.39
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.37
NOTUM Q6P988 1/20 0.37
MAP4K4 O95819 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12092479 0.77 RAB9A (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL9171005 0.77 RAB9A (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL1509570 0.77 RAB9A (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL16815729 0.77 RAB9A (0.54) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL30103039 0.74 RAB9A (0.45) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL28789382 0.74 RAB9A (0.56) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL21787722 0.74 RAB9A (0.50) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL2554715 0.74 RAB9A (0.45) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL1509577 0.73 SMN1; SMN2 (0.61) RAB9ANPC1SMN1; SMN2NFKB1NFKB2
SCHEMBL12089070 0.72 RAB9A (0.48) RAB9ANPC1SMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085347-A1 IL4I1 INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2025-04-24 WO disclosed
US-20240246937-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2024-07-25 US disclosed
EP-4329889-A1 IL4I1 INHIBITORS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2024-03-06 EP disclosed
WO-2022232333-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2022-11-03 WO disclosed
WO-2022227015-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2022-11-03 WO disclosed
US-5202321-A Antihistamine, antiallergens, antiinflammatory agents MERCK FROSST CANADA, INC. (CA) 1993-04-13 US disclosed
EP-0518426-A1 Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA INC. (CA) 1992-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246937-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 RAB9A 3769/4885NPC1 2807/4885SMN1; SMN2 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.